NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) ? Management of Immunotherapy-Related Toxicities Version 2.2019 — April 8, 2019 NCCN Continue Version 2.2019, 04/08/19 ? 2019 National Comprehensive Cancer Network (NCCN ), All rights reserved. NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. ? Printed by Maria Chen on 4/28/2019 9:59:12 PM. For personal use only. Not approved for distribution. Copyright ? 2019 National Comprehensive Cancer Network, Inc., All Rights Reserved. NCCN Guidelines Version 2.2019 Management of Immunotherapy-Related Toxicities NCCN Guidelines Index Table of Contents Discussion *John A. Thompson, MD/Chair ? ? ≡ Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance Marc S. Ernsto?, MD ? ≡ Roswell Park Cancer Institute Anthony J. Olszanski, MD, RPh ? Fox Chase Cancer Center Matthew Frigault, MD ? Massachusetts General Hospital Cancer Center Olalekan Oluwole, MD ? Vanderbilt-Ingram Cancer Center *Bryan J. Schneider, MD/Vice-Chair ? ≡ University of Michigan Rogel Cancer Center Sandip P. Patel, MD ? ? T *Julie Brahmer, MD/Vice-Chair ? ≡ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Brianna Ho?ner, MSN ? # University of Colorado Cancer Center UC San Diego Moores Cancer Center Sunil Reddy, MD ? Stanford Cancer Institute Christopher J. Hoimes, MD ? Case Comprehensive Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Stephanie Andrews, MS, ANP-BC ? Mo?tt Cancer Center Mabel Ryder, MD e Mayo Clinic Cancer Center Philippe Armand, MD, PhD ? Dana-Farber/Brigham and Women’s Cancer Center Bianca Santomasso, MD, PhD Y Memorial Sloan Kettering Cancer Center Mario Lacouture, MD v Memorial Sloan Kettering Cancer Center Scott Shofer, MD, PhD X Duke Cancer I